Samarbejdsaftale
Samarbejdsaftale
1. Parter
Mellem undertegnede Roche Pharmaceuticals a/s
(herefter kaldet ”Virksomheden”)
og
medundertegnede Øjenforeningen
(herefter kaldet ”Organisationen”)
(herefter i fællesskab benævnt ”Parterne”)
er der indgået følgende aftale om samarbejde.
2. Samarbejdsaftalens formål
Formålet med samarbejdsaftalen er at støtte Øjenforeningens deltagelse i Folkemøde 2023, herunder udgifter til rejse, ophold og også gennemførelse af synstest i det offentlige rum under Folkemødet.
3. Samarbejdsprojektets navn
Samarbejdsprojektets navn er ”Deltagelse på Folkemøde 2023”
4. Parternes rolle i samarbejdet
Virksomheden forpligter sig med nærværende samarbejdsaftale til i aftaleperioden at støtte foreningens deltagelse i Folkemødet 2023
Organisationen forpligter sig til at benytte støtten som angivet under formål.
5. Tidsramme
Samarbejdet, hvis nærmere formål og omfang er beskrevet i pkt. 2 og 4, skal afvikles i marts – juni 2023. Parternes rettigheder og forpligtelser i henhold til nærværende samarbejdsaftale løber fra underskriftsdato og indtil samarbejdsaftalens forpligtelser er opfyldt, medmindre andet udtrykkeligt er aftalt.
6. Finansiel ydelse
45.000,- DKK
7. Ikke-finansiel ydelse
N/A.
8. Offentliggørelse
Nærværende samarbejdsaftale er offentligt tilgængelig på Virksomhedens hjemmeside xxx.xxxxx.xx frem til 31. december 2023.
Jf. Etisk Nævn for Lægemiddelvirksomheders vejledning til ”Etiske regler for lægemiddelindustriens samarbejde med patientforeninger mv.” skal det understreges. at patientforeninger på sin hjemmeside skal offentliggøre alle økonomiske fordele, herunder økonomiske sponsorater (pengebeløb) og naturalier, som foreningen har modtaget fra lægemiddelvirksomheder, jf. reklamebekendtgørelsens § 21. Offentliggørelsen skal ske på en sådan måde, at størrelsen af økonomiske fordele fra hver enkelt virksomhed fremgår af hjemmesiden. Oplysningerne skal gøres tilgængelige på hjemmesiden senest én måned efter, at patientforeningen har modtaget den økonomiske fordel. Oplysningerne skal være tilgængelige på hjemmesiden i mindst to år.
9. Anvendelse af Organisationens navn
Organisationen accepterer, at Virksomheden anvender Organisationens navn i forbindelse med samarbejdet på Virksomhedens hjemmeside xxx.xxxxx.xx.
10. Uafhængighed og habilitet
Parterne erklærer ved sin underskrift, at det står Organisationen frit at samarbejde med flere lægemiddelvirksomheder, ligesom Virksomheden har mulighed for at samarbejde med en eller flere organisationer. Parterne erklærer samtidig, at der ikke i samarbejdet stilles krav om eneret i forhold til konkrete produkt- eller terapiområder.
Virksomheden erklærer ved sin underskrift af nærværende samarbejdsaftale ikke at stille betingelser for organisationens faglige og interessepolitiske standpunkter.
Virksomheden erklærer ved sin underskrift ikke at have et tillidshverv i Organisationen, der har betydning for nærværende samarbejdsaftale.
11. Misligholdelse
Såfremt en af Parterne misligholder sine forpligtelser i henhold til nærværende samarbejdsaftale, kan den ikke misligholdende part ophæve samarbejdsaftalen med øjeblikkelig virkning. Den ikke misligholdende part er i øvrigt berettiget til at bringe andre efter dansk ret til rådighed stående misligholdelsesbeføjelser til anvendelse, herunder retten til at kræve erstatning, uanset om aftalen ophæves.
12. Lovvalg
Nærværende samarbejdsaftale er i enhver henseende underlagt dansk ret.
13. Konfliktløsning
Såfremt tvister ikke kan bilægges igennem mægling, skal disse indbringes for Sø- og Handelsretten i København.
14. Underskrift
København,
10 marts 2023
Xxxxxxx Xxxxxxx
Direktør, Øįenforeningen
07 March 2023
København,
10 marts 2023
Xxxx Xxxxx Patient Partnership Lead, Roche a/s | Xxxxx Xxxxxxx Xxxxxxxxxxx Head of Partnership & Digital, Roche a/s |
Certificate Of Completion
Envelope Id: CD7E0EB4046547B9B115637BF752D089 Status: Completed Subject: Complete with DocuSign: Øjenforeningen_Folkemøde_2023.pdf
Source Envelope:
Document Pages: 4 Signatures: 3 Envelope Originator:
Certificate Pages: 4 Initials: 0 Xxxxxxx Xxxxxxxx
AutoNav: Enabled
EnvelopeId Stamping: Enabled
Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna
Xxxxxxxxxxxxxxxxx 000
Basel, Basel-Stadt 4070 xxxxxxx.xxxxxxxx@xxxxx.xxx IP Address: 196.3.50.248
Record Tracking
Status: Original
3/7/2023 2:56:59 PM
Holder: Xxxxxxx Xxxxxxxx
Location: DocuSign
Signer Events Signature Timestamp
xxxx Xxxxx xxxx.xxxxx@xxxxx.xxx
Security Level: Email, Account Authentication (None)
Signature Adoption: Pre-selected Style Using IP Address: 196.3.50.247
Sent: 3/7/2023 2:58:03 PM Viewed: 3/7/2023 3:05:27 PM Signed: 3/7/2023 3:05:50 PM
Electronic Record and Signature Disclosure:
Accepted: 3/7/2023 3:08:43 PM
ID: 4991e54b-9f09-4beb-96c1-ce3e65f2b4e3 Company Name: X. Xxxxxxxx-La Roche Ltd
Xxxxx Xxxxxxxxxxx xxxxx.xxxxxxxxxxx@xxxxx.xxx Head of Innovation Lab
Security Level: Email, Account Authentication
(None) Signature Adoption: Pre-selected Style
Using IP Address: 196.3.50.248
Sent: 3/7/2023 3:05:53 PM Viewed: 3/10/2023 11:22:24 AM Signed: 3/10/2023 11:22:49 AM
Electronic Record and Signature Disclosure:
Accepted: 3/10/2023 11:23:26 AM
ID: 4a5e2f71-7a3d-4d70-9c58-844886b81d61
Company Name: X. Xxxxxxxx-La Roche Ltd
Xxxxxxx Xxxxxxx xx@xxxxxxxxxxxxxx.xx Direktør
Security Level: Email, Account Authentication
(None) Signature Adoption: Drawn on Device
Using IP Address: 89.221.164.66
Sent: 3/10/2023 11:22:53 AM Viewed: 3/10/2023 12:06:37 PM Signed: 3/10/2023 12:06:52 PM
Electronic Record and Signature Disclosure:
Accepted: 3/10/2023 12:06:37 PM
ID: 8bef8fd4-69d9-4adc-bb3a-56c3a93a4c65 Company Name: X. Xxxxxxxx-La Roche Ltd
In Person Signer Events | Signature | Timestamp |
Editor Delivery Events | Status | Timestamp |
Agent Delivery Events | Status | Timestamp |
Intermediary Delivery Events | Status | Timestamp |
Certified Delivery Events | Status | Timestamp |
Carbon Copy Events | Status | Timestamp |
Witness Events | Signature | Timestamp |
Notary Events | Signature | Timestamp |
Envelope Summary Events | Status | Timestamps |
Envelope Sent | Hashed/Encrypted | 3/7/2023 2:58:03 PM |
Certified Delivered | Security Checked | 3/10/2023 12:06:37 PM |
Signing Complete | Security Checked | 3/10/2023 12:06:52 PM |
Completed | Security Checked | 3/10/2023 12:06:52 PM |
Payment Events | Status | Timestamps |
Electronic Record and Signature Disclosure | ||
Electronic Record and Signature Disclosure created on: 1/3/2019 2:16:57 PM Parties agreed to: xxxx Xxxxx, Xxxxx Xxxxxxxxxxx, Xxxxxxx Xxxxxxx
Guidelines for the use of the DocuSign electronic signing system within X. Xxxxxxxx-La Roche and companies of the Roche Group
LEGAL DISCLOSURE
By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.
I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.
CONSUMER DISCLOSURE
From time to time, X. Xxxxxxxx-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.
Consequences of changing your mind
To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.
All notices and disclosures will be sent to you electronically
Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.
How to contact us
You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.
To advise us of your new email address
To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.
To withdraw your consent
To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.
Acknowledging your access and consent to receive materials electronically
To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.
By checking the 'I agree' box, I confirm that:
● I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
● I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
● Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
● I acknowledge the information included in the† DocuSign Privacy Policy